QYR-Xiaomanのブログ

mRNA Vaccines for Animals Market Summary

According to the new market research report “Global mRNA Vaccines for Animals Market Report 2024-2030”, published by QYResearch, the global mRNA Vaccines for Animals market size is projected to reach USD 4.08 billion by 2034, at a CAGR of 29.7% during the forecast period.

Figure.   Global mRNA Vaccines for Animals Market Size (US$ Million), 2019-2030

Above data is based on report from QYResearch: Global mRNA Vaccines for Animals Market Report 2024-2030 (published in 2024). If you need the latest data, plaese contact QYResearch.

Figure.   Global mRNA Vaccines for Animals Top 11 Players Ranking and Market Share (Ranking is based on the revenue of 2023, continually updated)

Above data is based on report from QYResearch: Global mRNA Vaccines for Animals Market Report 2024-2030 (published in 2024). If you need the latest data, plaese contact QYResearch.

According to QYResearch Top Players Research Center, the global key manufacturers of mRNA Vaccines for Animals include Merck Animal Health, Ceva Animal Health, Tiba Biotechnology, Jinyu Bio-technology, Harbin Enwei Biological Pharmaceutical, etc. In 2027, the global top five players had a share approximately 97.0% in terms of revenue.

Figure.   mRNA Vaccines for Animals, Global Market Size, Split by Product Segment

Based on or includes research from QYResearch: Global mRNA Vaccines for Animals Market Report 2024-2030.

In terms of product type, currently Self-amplifying mRNA vaccines is the largest segment, hold a share of 70.0%.

Figure.   mRNA Vaccines for Animals, Global Market Size, Split by Application Segment

Based on or includes research from QYResearch: Global mRNA Vaccines for Animals Market Report 2024-2030.

In terms of product application, currently Swine is the largest segment, hold a share of 23.8%. 

Figure.   mRNA Vaccines for Animals, Global Market Size, Split by Region

Based on or includes research from QYResearch: Global mRNA Vaccines for Animals Market Report 2024-2030.

Market Drivers:

Technological breakthroughs are driving innovation in vaccine models:

mRNA technology, validated in human COVID-19 vaccines, has been widely recognized for its effectiveness, safety, and rapid development.

Animal vaccines no longer rely on traditional attenuation and inactivation processes, enabling rapid synthesis, precise design, and high-throughput screening, significantly improving vaccine development efficiency.

Continuous advances in delivery technologies (such as LNPs) and mRNA stability technologies are accelerating the application and implementation of animal vaccines.

Animal diseases are numerous, mutate rapidly, and demand for vaccines is high:

Animal infectious diseases such as swine fever, PRRS, PED, and avian influenza frequently mutate, making it difficult for traditional vaccines to quickly adapt.

mRNA vaccines can complete candidate vaccine design and pilot production within 2–6 weeks, enabling rapid response to outbreaks or regional variants.

Some countries have included mRNA vaccines in their strategic animal disease prevention and control tools.

Short R&D cycles meet the rapid updating needs of industrial vaccines:

mRNA vaccines typically take 30–60 days from design to pilot batch production, significantly faster than protein subunit or viral vector vaccines. For vaccines requiring annual strain updates (such as avian influenza and swine flu), the mRNA platform offers a natural advantage.

Strong Multivalent Vaccine Development Capabilities:

mRNA vaccine technology allows for the integration of multiple antigen codes within a single molecule or formulation, making the development of multivalent vaccines more efficient.

Global Animal Vaccine Market Expansion:

With the rise of the pet economy, the expansion of large-scale farming, and growing global awareness of animal health, the animal vaccine market is growing steadily.

The global animal vaccine market is projected to exceed $15 billion by 2030, providing greater potential for mRNA technology.

Increased Policy and Financial Support:

The U.S. Department of Agriculture (USDA), the European Union, and other countries have initiated review and guidance policies for mRNA animal vaccines.

Many governments have included mRNA vaccines in their "Next Generation Biosafety Vaccine" strategic plans and are providing R&D subsidies and fast-track trial approvals.

Driven by Cross-Border Capital and Technology Integration:

Many companies previously focused on human mRNA are entering the animal sector through joint ventures, licensing, and incubation. Emerging technologies such as synthetic biology, AI protein design, and cold chain logistics are deeply integrated with vaccine development to accelerate the maturity of the industry.

Restraint:

Core technological shortcomings remain:

mRNA modification technology (such as pseudouridine modification) and patents for efficient delivery systems are still monopolized by leading companies (such as BioNTech and Moderna), posing risks. The development of specialized adjuvants for animal vaccines is lagging, impacting immune efficacy.

Lack of cold chain storage and transportation capabilities:

mRNA vaccines require low-temperature storage and transportation at -20°C to -70°C, making it difficult to maintain cold chain integrity in decentralized livestock farming environments (especially in rural areas).

The registration review system needs improvement: Current laws and regulations have yet to detail the review standards for new vaccines such as mRNA, and the lack of animal testing data guidelines prolongs the time to market.

Limited market willingness to pay:

Vaccines for commercial animals (pigs and poultry) are highly price sensitive. Traditional inactivated vaccines cost only 0.3-1 yuan per dose, making it difficult to reduce the cost of mRNA vaccines to competitive levels in the short term.

About The Authors

The author of this article is Ms. Tuo

Possessing rich research experience in the machinery and equipment industry and strong customer service awareness.

Research fields: machinery and equipment, consumer goods industry.

Leading projects include:

Tunable Laser Sources, Ore Sorting Machine, Rotor Desiccant Dehumidifiers, Electric Bus Pantograph Charger, Indoor Sauna Room, Pets Pheromones, Microphysiological System, etc.

Cooperating customers:

Huawei, Hitachi, Panasonic, Honda, etc.

To contact us and get this report: https://www.qyresearch.com/contact-us

About Us：

QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 9 countries  (include United States, Germany, Switzerland, Japan, Korea, China, India  and so on)  and business partners in over 30 countries. We have provided industrial information services to more than 68,000 companies in over the world.

Contact Us:

If you have any queries regarding this report or if you would like further information, please contact us:

QY Research Inc.

Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States

E-mail: tytaoyue@qyresearch.com, global@qyresearch.com 

Tel: 001-626-295-2442(US)  0086-159 1594 1389(CN)

EN: https://www.qyresearch.com